Quantcast

Latest Ketamine Stories

2011-06-22 06:30:00

EVANSTON, Ill., June 22, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13. GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), is initially being developed as a therapy for patients who are not achieving an adequate response to their current...

2011-06-17 13:21:26

UT Southwestern Medical Center scientists are shedding new light on why the anesthetic drug ketamine produces a fast-acting antidepressant response in patients with treatment-resistant depression. The drug's robust effect at low doses as a fast-acting antidepressant potentially has use in emergency rooms with high-risk patients. "Ketamine produces a very sharp increase that immediately relieves depression," said Dr. Lisa Monteggia, associate professor of psychiatry at UT Southwestern and...

2010-12-07 06:30:00

MIAMI and EVANSTON, Ill., Dec. 7, 2010 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, reported that data being presented today at the 49th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) further confirm that its lead antidepressant candidate GLYX-13 appears free of the behavioral impairment and abuse potential that have limited the clinical utility of other NMDA receptor...

2010-11-17 06:30:00

SAN DIEGO and EVANSTON, Ill., Nov. 17, 2010 /PRNewswire/ -- Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.* Numerous studies have shown that ketamine has a markedly faster...

2010-10-19 17:19:59

Procedural sedation and analgesia is an essential element of care for children requiring painful procedures in the emergency department. The practice of combining ketamine and propofol, two common medications used in emergency departments, has become more popular. However, until recently, it was unclear whether this practice was superior to the use of either agent alone, especially in children. Research led by Drs. Amit Shah, Gregory Mosdossy and Michael Rieder of the Schulich School of...

2010-10-12 18:13:41

A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia. Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively...

2010-08-31 06:30:00

EVANSTON, Ill., Aug. 31 /PRNewswire/ -- Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch." They were chosen by a committee that included Windhover Information, the publishers of IN...

95b48d50491728f9bff5589878bbd3b91
2010-08-18 13:30:00

Swiss scientists suggested Wednesday that psychedelic drugs like LSD, ketamine and magic mushrooms could be combined with psychotherapy to treat people suffering from depression, compulsive disorders or chronic pain. Research into the effects of psychedelics has been restricted because of the negative connotations of drugs, but the scientists said more studies into their clinical potential were now justified. The scientists reported that recent brain imaging studies show that psychedelics...

2010-08-03 14:08:08

A single intravenous dose of the anesthetic agent ketamine appears to reduce symptoms of depression within 40 minutes among those with bipolar disorder who have not responded to other treatments, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals. "Bipolar disorder is one of the most severe psychiatric disorders and ranks in the top 10 causes of medical disability worldwide," the authors write as background information in the...

2010-06-17 06:30:00

BOCA RATION, Fla. and EVANSTON, Ill., June 17 /PRNewswire/ -- Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist (GFPA) selective modulator of the NMDA receptor that is being developed initially for use in depression as...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related